EUVIMEDEUVIMED entdecken
Crossref

CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection

Kyoto Matsudo, Kazuki Takada, Asato Hashinokuchi, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Tomoyoshi Takenaka, Mototsugu Shimokawa, Yoshinao Oda, Tomoharu Yoshizumi

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02771-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Kyoto Matsudo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lung Neoplasms, Adenocarcinoma, Receptors, Virus. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CD155 has been identified as a ligand for T-cell immunoreceptor with Ig and ITIM domains. Herein, we investigated the relationship between the expressions of CD155 and programmed cell death-ligand 1 (PD-L1) and clinical outcomes in patients with surgically resected lung adenocarcinoma. METHODS: This study included 426 patients diagnosed with pathological stage (pStage) I-III lung adenocarcinoma who underwent surgery at Kyushu University Hospital. The number of tumor cells expressing CD155 and PD-L1 was assessed by immunohistochemistry, and the clinical significance of CD155 expression and CD155/PD-L1 co-expression in prognosis was investigated. RESULTS: Among the enrolled cohort, 320 (75.1%), 60 (14.1%), and 46 (10.8%) patients were diagnosed with pStage I, II, and III, respectively. Tissues from 112 patients (26.3%) were classified as having high CD155 expression. Co-expression of CD155 and PD-L1 was observed in 44 patients (10.3%). The High CD155 and CD155/PD-L1 co-expression groups had significantly poorer prognosis in pStage I-III lung adenocarcinoma. However, subgroup analysis revealed that the clinical significance of both CD155 expression and CD155/PD-L1 co-expression differed widely between patients with pStage I and II-III. Multivariate Cox proportional hazards regression analyses showed that high CD155 expression and CD155/PD-L1 co-expression were not independent poor prognostic factors in pStage II-III lung adenocarcinoma. CONCLUSION: Our findings suggest that neither CD155 expression or CD155/PD-L1 co-expression are associated with poor prognosis in pStage II-III lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLung NeoplasmsAdenocarcinomaReceptors, VirusHumansMaleFemaleMiddle AgedPrognosisAgedAdenocarcinoma of LungNeoplasm StagingAdultBiomarkers, TumorAged, 80 and over

Stichwörter der Autor:innen

AdenocarcinomaCD155Co-expressionImmune checkpoint inhibitorPD-L1

Substanzen

B7-H1 Antigenpoliovirus receptorCD274 protein, humanReceptors, VirusBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
  • Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. takenaka.tomoyoshi.473@m.kyushu-u.ac.jp.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Matsudo, K., Takada, K., Hashinokuchi, A., Nagano, T., Kinoshita, F., Akamine, T., Kohno, M., Takenaka, T., Shimokawa, M., Oda, Y., & Yoshizumi, T. (2025). CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02771-9

Vancouver

Matsudo K, Takada K, Hashinokuchi A, Nagano T, Kinoshita F, Akamine T, et al. CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02771-9

BibTeX
@article{Matsudo2025,
  author = {Matsudo, Kyoto and Takada, Kazuki and Hashinokuchi, Asato and Nagano, Taichi and Kinoshita, Fumihiko and Akamine, Takaki and Kohno, Mikihiro and Takenaka, Tomoyoshi and Shimokawa, Mototsugu and Oda, Yoshinao and Yoshizumi, Tomoharu},
  title = {CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02771-9}
}
Kostenlos starten →